Extended-Release Calcifediol: A Data Journey from Phase 3 Studies to Real-World Evidence Highlights the Importance of Early Treatment of Secondary Hyperparathyroidism
Authors:
- Domenico MeranteDMDomenico Merante
- Henrik SchouHSHenrik Schou
- Isabelle MorinIMIsabelle Morin
- Marius ManuMMMarius Manu
- Akhtar AshfaqAAAkhtar Ashfaq
- Charles BishopCBCharles Bishop
- Stephen StrugnellSSStephen Strugnell
Open Access
- 24 April 2024
- journal article
- review article
- Published by S. Karger AG in Nephron
- Vol. 148 (10) , 657-666
Abstract
Background: Early secondary hyperparathyroidism (SHPT) diagnosis and treatment are crucial to delay the progression of SHPT and related complications, in particular, cardiovascular events and bone fractures. Extended-release calcifediol (ERC) has been developed for the treatment of SHPT in patients with stage 3/4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI). Summary: This review compares baseline characteristics and treatment responses of SHPT patients receiving ERC in phase 3 studies with those treated with ERC in a real-world study. Mean ± standard deviation baseline parathyroid hormone (PTH) levels were 147 ± 56 pg/mL and 148 ± 64 pg/mL in the phase 3 ERC cohorts, and 181 ± 98 pg/mL in the real-world study. Other baseline laboratory parameters were consistent between the clinical and real-world studies. ERC treatment increased 25-hydroxyvitamin D (25(OH)D) and significantly reduced PTH levels, regardless of baseline CKD stage, in all studies. In the pooled phase 3 per-protocol populations, 74% of the ERC cohort were uptitrated to 60 μg/day after 12 weeks at 30 μg/day, 97% attained 25(OH)D levels ≥30 ng/mL, and 40% achieved ≥30% PTH reduction. Despite a much lower rate of uptitration in the real-world study, 70% of patients achieved 25(OH)D levels ≥30 ng/mL, and 40% had a ≥30% reduction in PTH. Key Messages: These data establish a “continuum” of clinical and real-world evidence of ERC effectiveness for treating SHPT, irrespective of CKD stage, baseline PTH levels, and ERC dose. This evidence supports early treatment initiation with ERC, following diagnosis of SHPT, VDI, and stage 3 CKD, to delay SHPT progression.Keywords
This publication has 37 references indexed in Scilit:
- Where are we now? Emerging opportunities and challenges in the management of secondary hyperparathyroidism in patients with non-dialysis chronic kidney diseaseJournal Of Nephrology, 2021
- Surgical Management of Secondary HyperparathyroidismKidney International Reports, 2021
- PTH suppression by calcitriol does not predict off‐target actions in experimental CKDPharmacology Research & Perspectives, 2020
- Parathyroid hormone independently predicts fracture, vascular events, and death in patients with stage 3 and 4 chronic kidney diseaseOsteoporosis International, 2019
- Is calcifediol better than cholecalciferol for vitamin D supplementation?Osteoporosis International, 2018
- Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it mattersKidney International, 2017
- Modified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulationThe Journal of Steroid Biochemistry and Molecular Biology, 2015
- Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too lowJournal Of Nephrology, 2015
- Laboratory Abnormalities in CKD-MBD: Markers, Predictors, or Mediators of Disease?Seminars in Nephrology, 2014
- Vitamin D Therapy and Cardiac Structure and Function in Patients With Chronic Kidney DiseaseJAMA, 2012